J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales

Key Takeaways J&J posted Q4 EPS of $2.46, beating estimates, as earnings rose 20.6% year over year.JNJ's Innovative Medicines sales climbed 10%, driven by Darzalex, Tremfya and Erleada growth.Oncology drugs like Darzalex and Carvykti delivered strong gains, offsetting Stelara declines.Johnson & Johnson’s (JNJ) fourth-quarter 2025 earnings came in at$ 2.46 per share, which beat the Zacks Consensus Estimate of $2.43. Earnings rose 20.6% from the year-ago period.Adjusted earnings exclude intangible amortizatio ...